Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tarsus Pharmaceuticals (TARS – Research Report), Kiniksa Pharmaceuticals (KNSA – Research Report) and Danaher (DHR – Research Report).
Tarsus Pharmaceuticals (TARS)
In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Tarsus Pharmaceuticals, with a price target of $54.00. The company’s shares closed last Tuesday at $18.04.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of
Currently, the analyst consensus on Tarsus Pharmaceuticals is a Strong Buy with an average price target of $49.83, representing a 140.6% upside. In a report released yesterday, LifeSci Capital also reiterated a Buy rating on the stock with a $70.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Kiniksa Pharmaceuticals (KNSA)
In a report released yesterday, Geoff Meacham from Bank of America Securities reiterated a Buy rating on Kiniksa Pharmaceuticals, with a price target of $28.00. The company’s shares closed last Tuesday at $19.48.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kiniksa Pharmaceuticals with a $27.67 average price target, which is a 64.3% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $32.00 price target.
Danaher (DHR)
In a report released yesterday, Michael Ryskin from Bank of America Securities reiterated a Hold rating on Danaher, with a price target of $280.00. The company’s shares closed last Tuesday at $255.70.
According to TipRanks.com, Ryskin is a 2-star analyst with an average return of
Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $282.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TARS:
- Tarsus Pharmaceuticals Plunges despite FDA Win
- FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
- Oppenheimer Says These 2 Stocks Could Double Your Money — Here’s Why They Could Jump
- Tarsus Pharmaceuticals initiated with an Outperform at William Blair
- Tarsus Pharmaceuticals management to meet with Oppenheimer
